Company
Valeo Pharma Inc.
TSX:VPH
Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec, Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.
32 stories · page 2 of 2
Valeo Pharma says Frederic Fasano has stepped down as the company's president and chief operating officer
Fasano's duties and responsibilities are being integrated and assumed by the company's CEO, Steve Saviuk and its chief commercial officer, Kyle Steiger
Valeo Pharma raises Q4 and FY2022 revenue guidance to record levels
"Our lead products have delivered the strong growth we forecasted for 2022," said Steve Saviuk, Valeo Pharma’s CEO
Valeo Pharma enters into Canadian commercial services agreement with Veru for sabizabulin in COVID-19 treatment
"Provincial healthcare systems across the country are still battling with high numbers of COVID-19 hospitalized patients and related deaths,” Valeo CEO Steve Saviuk said
Valeo Pharma announces record revenue of $6.1M for 3Q; forecasts more than $11M in revenue for 4Q
“We are also very proud to have added three core commercial assets during this third quarter that will help more than double our annual revenues over the coming year," said Valeo CEO Steve Saviuk
Valeo Pharma announces appointment of Kyle Steiger to role of senior vice-president and CCO
Valeo Pharma also announced that Jean-Francois Fournier has joined as its new business unit head for the ophthalmology section
Valeo Pharma secures loan from Sagard Healthcare Partners to fund acquisitions of pharmaceutical therapies
Sagard will provide Valeo with up to US$40 million, with US$30 million provided fully funded on the closing, and an additional US$10 million available
Valeo Pharma enters into agreement with Kaleo to produce epinephrine auto-injector for Canadian market
Kirkland, Quebec-based Valeo Pharma will be responsible for all commercial and medical activities for ALLERJECT in Canada for an initial period of 10 years
Valeo Pharma enters commercialization and supply agreement with Novartis Canada for two ophthalmic therapies
Under the agreement, Valeo becomes the exclusive distributor of XIIDRA and SIMBRINZA in Canada, making it responsible for all commercial and medical activities
Valeo Pharma posts 80% increase in 2Q revenue as lead products report strong growth
“Valeo remains focused on maximizing market share of its lead products while also actively looking to add strategic assets to leverage and take full advantage of its corporate structure and commercial platform," the company's CEO Steve Savi
NA Proactive news snapshot: Chesapeake Financial Shares, Doré Copper Mining, Sidus Space, NEO Battery Materials, Valeo Pharma, Looking Glass Labs UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires